Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families

[1]  A. Shaaban,et al.  Role of rapid sequence whole-body MRI screening in SDH-associated hereditary paraganglioma families , 2013, Familial Cancer.

[2]  J. Hamming,et al.  High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations , 2012, European Journal of Human Genetics.

[3]  M. Mannelli,et al.  Updated and New Perspectives on Diagnosis, Prognosis, and Therapy of Malignant Pheochromocytoma/Paraganglioma , 2012, Journal of oncology.

[4]  J. Carrasquillo,et al.  Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. , 2012, Journal of the National Cancer Institute.

[5]  M. Fassnacht,et al.  Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.

[6]  M. Kupferman,et al.  A novel SDHB mutation associated with hereditary head and neck paraganglioma , 2011, The Laryngoscope.

[7]  J. Schiffman.  No child left behind in SDHB testing for paragangliomas and pheochromocytomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Beyene,et al.  Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. , 2011, The Lancet. Oncology.

[9]  S. Bornstein,et al.  Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. , 2010, Endocrine-related cancer.

[10]  J. Bayley,et al.  Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma , 2010, Familial Cancer.

[11]  K. Pacak,et al.  SDH-related pheochromocytoma and paraganglioma. , 2010, Best practice & research. Clinical endocrinology & metabolism.

[12]  M. Merino,et al.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. , 2008, The Journal of clinical endocrinology and metabolism.

[13]  D. Marsh,et al.  Genetic Testing in Pheochromocytoma‐ and Paraganglioma‐Associated Syndromes , 2006, Annals of the New York Academy of Sciences.

[14]  K. Byth,et al.  Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  C. Eng,et al.  Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. , 2004, JAMA.

[16]  G. Chatellier,et al.  Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators. , 2013, The Journal of clinical endocrinology and metabolism.

[17]  K. Nathanson,et al.  Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. , 2012, Cancer genetics.

[18]  J. Carrasquillo,et al.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. , 2009, The Journal of clinical endocrinology and metabolism.

[19]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .